Loading clinical trials...
Loading clinical trials...
A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine
Conditions
Interventions
Eptinezumab
Placebo
Locations
57
United States
Alabama Clinical Therapeutics
Birmingham, Alabama, United States
Arizona Research Center
Phoenix, Arizona, United States
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States
Advanced Research Center
Anaheim, California, United States
The Neurology Center of Southern California - Carlsbad
Carlsbad, California, United States
Excell research Inc
Oceanside, California, United States
Start Date
November 7, 2019
Primary Completion Date
July 8, 2020
Completion Date
July 8, 2020
Last Updated
August 17, 2021
NCT06735833
NCT06241313
NCT07018713
NCT06641466
NCT04715685
NCT07476053
Lead Sponsor
H. Lundbeck A/S
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions